东莨菪碱 API 市场：按形式、按纯度、按生产规模、按地区 - 规模、份额、展望、机会分析，2022-2030 年

东莨菪碱是一种从紫茎泽兰植物中提取的生物碱药物，用于治疗噁心和晕动病，并在眼科手术中用于散瞳。东莨菪碱属于一类称为抗胆碱能药的药物。东莨菪碱是一种从茄科植物中分离出来的托烷生物碱，与阿托品和天仙子胺一样，在结构上模仿天然神经递质乙□胆碱。通过抑制神经递质乙□胆碱的活性，该药物通过刺激大脑中引发噁心和呕吐、肺部、胃肠道和泌尿道的不自主肌肉运动的部分发挥作用。东莨菪碱在医疗环境中用作镇静剂和催眠剂，有时与吗啡一起用于缓解疼痛。东莨菪碱也被规定为抑郁症、哮喘、戒烟辅助剂和与化疗相关的噁心的“标籤外”治疗。

市场动态

东莨菪碱通过其缓解焦虑作用（抗焦虑作用）有效缓解抑郁和焦虑症状。因此，由于越来越多的人患有焦虑症，预计预测期内的市场增长。例如，根据美国焦虑和抑郁协会的数据，焦虑症是美国最常见的精神疾病，每年影响大约 4000 万 18 岁及以上的成年人（占人口的 18.1%）。我在这里。

此外，预计在预测期内，越来越多地采用透皮贴剂等给药系统也有望推动市场增长。东莨菪碱透皮贴剂用于预防与麻醉和手术恢復相关的晕动病、噁心和呕吐。

这项研究的主要特点

• 本报告对全球东莨菪碱 API 市场进行了深入分析，提供了以 2021 年为基准年的预测期（2022-2030 年）的市场规模和復合年增长率 (CAGR%)。.
• 解释了不同细分市场的潜在创收机会，并描述了针对该市场的有吸引力的投资建议矩阵。
• 它还提供有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
• 根据以下参数介绍全球东莨菪碱 API 市场的主要参与者 - 公司亮点、产品组合、主要亮点、财务业绩和战略。
• 本研究涵盖的主要公司包括 Phytex Australia、Aspen Holdings、LGM Pharma、Midas Pharma GmbH、Transo-Pharm Handels-GmbH、Aktin Chemicals, Inc、Merck KgaA、Alchem International Pvt. Ltd.、 Tiefenbacher API+Ingredients GmbH & Co. KG、Spectrum Chemical、Vital Laboratories Pvt Ltd、Clearsynth、Prism Industries Ltd、Alkaloids Corporation. 和 Manus Aktteva Biopharma LLP
• 这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。看来。
• 《全球东莨菪碱 API 市场报告》面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
• 利益相关者可以通过用于分析全球东莨菪碱 API 市场的各种战略矩阵来促进他们的决策。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写说明

第二章市场展望

• 报告内容
  • 市场定义和范围
• 执行摘要
  • 市场概况：按形态分类
  • 市场概况：按纯度分类
  • 市场概况：按生产规模
  • 市场概况：按地区
• 连贯机会图 (COM)

第3章市场动态、规律及趋势分析

• 市场动态
  • 司机
  • 约束因素
  • 市场机会
• 影响分析
• 害虫分析
• 监管情景
• 流行病学
• 收购/合同方案
• 主要亮点/发展
• 东莨菪碱 API 市场的问题

第 4 章东莨菪碱 API 的全球市场 - 冠状病毒 (COVID-19) 大流行的影响

• 经济影响
• COVID-19 的流行病学特征
• 供需分析

第 5 章。全球东莨菪碱 API 市场，按形式，2017-2030

• 粉末
• 液体

第 6 章东莨菪碱 API 的全球市场：按纯度分类，2017-2030

• 99% 或更多
• 98% 或更多

第 7 章 2017-2030 年按生产规模分列的东莨菪碱原料药全球市场

• 工业规模
• 中试规模
• 实验室规模

第 8 章按地区分列的东莨菪碱原料药全球市场，2017-2030

• 北美
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地区
• 欧洲
• 英国
• 德国
• 意大利
• 法国
• 西班牙
• 俄罗斯
• 其他欧洲地区
• 亚太地区
• 中国
• 印度
• 日本
• 东盟
• 澳大利亚
• 韩国
• 其他亚太地区
• 中东
• 海湾合作委员会
• 以色列
• 其他中东地区
• 非洲
• 北非
• 中非
• 南非

第9章竞争格局

• Phytex Australia.
• Aspen Holdings
• LGM Pharma
• Midas Pharma GmbH
• Transo-Pharm Handels-GmbH
• Aktin Chemicals,Inc
• Merck KGaA
• Alchem International Pvt. Ltd.
• Tiefenbacher API+Ingredients GmbH & Co. KG
• Spectrum Chemical
• Vital Laboratories Pvt Ltd
• Clearsynth
• Prism Industries Ltd
• Alkaloids Corporation.
• Manus Aktteva Biopharma LLP

第 10 章

• 调查方法
• 关于出版商

Scopolamine is an alkaloid drug extracted from a plant called henbane to treat nausea and motion sickness and further to dilate the pupil in ophthalmic procedures. Scopolamine belongs to a class of drugs called anticholinergic. Scopolamine is a tropane alkaloid isolated from members of the Solanaceae family of plants, similar to atropine and hyoscyamine, all of which structurally mimic the natural neurotransmitter acetylcholine. It works by blocking the activity of the neurotransmitter acetylcholine, which stimulates the part of the brain that triggers nausea and vomiting, involuntary muscle movement in the lungs, and the gastrointestinal and urinary tracts. Scopolamine is also used in medicine as a sedative or hypnotic and sometimes with morphine to relieve pain. Scopolamine has also been prescribed 'off label' for depression, asthma, as a smoking-cessation remedy, and to relieve the nausea that accompanies chemotherapy

Market Dynamics

Scopolamine is effective in reducing depression and anxiety symptoms due to its anxiety-reducing (anxiolytic) effects. Thus the increasing number of people suffering from anxiety is expected to drive the market growth over the forecast period. For instance, according to the Anxiety and Depression Association of America, anxiety disorders are the most common mental illness in the U.S. affecting about 40 million adults aged 18 years and older, or 18.1% of the population every year in the U.S.

Moreover, increasing adoption of drug delivery systems such as transdermal patches is expected to drive the market growth over the forecast period. The scopolamine transdermal skin patch is used to prevent nausea and vomiting caused by motion sickness or recovery from anesthesia and surgery.

Key features of the study:

• This report provides in-depth analysis of the global scopolamine API market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global scopolamine API market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Phytex Australia., Aspen Holdings, LGM Pharma, Midas Pharma GmbH, Transo-Pharm Handels-GmbH, Aktin Chemicals,Inc, Merck KgaA, Alchem International Pvt. Ltd., Tiefenbacher API + Ingredients GmbH & Co. KG, Spectrum Chemical, Vital Laboratories Pvt Ltd, Clearsynth, Prism Industries Ltd, Alkaloids Corporation., and Manus Aktteva Biopharma LLP
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global scopolamine API market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global scopolamine API market

Detailed Segmentation:

• Global Scopolamine API Market, By Form:
  • Powder
  • Liquid
• Global Scopolamine API Market, By Purity:
  • ≥99%
  • ≥ 98%
• Global Scopolamine API Market, By Scale of Production:
  • Industrial scale
  • Pilot scale
  • Laboratory scale
• Global Scopolamine API Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Phytex Australia.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Aspen Holdings
  • LGM Pharma
  • Midas Pharma GmbH
  • Transo-Pharm Handels-GmbH
  • Aktin Chemicals,Inc
  • Merck KGaA
  • Alchem International Pvt. Ltd.
  • Tiefenbacher API + Ingredients GmbH & Co. KG
  • Spectrum Chemical
  • Vital Laboratories Pvt Ltd
  • Clearsynth
  • Prism Industries Ltd
  • Alkaloids Corporation.
  • Manus Aktteva Biopharma LLP

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Form
  • Market Snapshot, By Purity
  • Market Snapshot, By Scale of Production
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• PEST Analysis
• Regulatory Scenario
• Epidemiology
• Acquisition/Agreement Scenario
• Key Highlights/Developments
• Challenges in Scopolamine API Market

4. Global Scopolamine API Market- Impact of Coronavirus (Covid-19) Pandemic

• Economic Impact
• COVID-19 Epidemiology
• Demand and Supply Analysis

5. Global Scopolamine API Market, By Form, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Powder
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Liquid
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Scopolamine API Market, By Purity, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• ≥99%
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• ≥ 98%
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Scopolamine API Market, By Scale of Production, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Industrial scale
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Pilot scale
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Laboratory scale
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Scopolamine API Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Purity, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Scale of Production, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Purity, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Scale of Production, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Purity, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Scale of Production, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Purity, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Scale of Production, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Purity, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Scale of Production, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Purity, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Scale of Production, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Phytex Australia.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Aspen Holdings
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• LGM Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Midas Pharma GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Transo-Pharm Handels-GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Aktin Chemicals,Inc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck KGaA
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Alchem International Pvt. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Tiefenbacher API + Ingredients GmbH & Co. KG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Spectrum Chemical
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Vital Laboratories Pvt Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Clearsynth
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Prism Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Alkaloids Corporation.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Manus Aktteva Biopharma LLP
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us